Abbott may join the divestiture party

Market chatter is beginning to stir concerning Abbott Labs (ABT -0.3%) potential sale of its established drug portfolio. Some observers believe it could fetch as much as $5B. The company is rumored to be working with Morgan Stanley on the deal.

From other sites
Comments (5)
  • bberuch
    , contributor
    Comments (314) | Send Message
    very confused as to what,why, and anticipated benefits
    2 May 2014, 04:17 PM Reply Like
  • timetosave
    , contributor
    Comments (36) | Send Message
    Likely sell it to AbbVie!
    2 May 2014, 05:13 PM Reply Like
  • snoopy44
    , contributor
    Comments (1373) | Send Message
    I am confused. The only drugs still in the ABT (not ABBV) pipeline would be the generics. Is that what they are talking about? Actually, when ABT split in two I was very surprised that the generics were not included in the Abbvie piece of the business. Generics have some of the lowest profit margins in the business. Why would you want to keep that? It's not like you are trying to become a TEVA or anything. It's all about the nutritional products now. How do generics relate to that?
    2 May 2014, 05:59 PM Reply Like
  • tomazwi
    , contributor
    Comment (1) | Send Message
    Look @ ACT going overseas, for Tax breaks, ABT may do it , by selling.
    3 May 2014, 10:28 AM Reply Like
    , contributor
    Comments (4) | Send Message
    Generics have low margin, but wide volumes; so they could be interesting particularly in the developing countries. Apart from this; how could this eventual deal create value for the stockholders? Megadividend? Or what else?
    3 May 2014, 10:32 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs